

Gambro BCT announces red blood cell Pathogen Eradication Technology (PET) performance

Stockholm, Sweden, November 3, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced its red blood cell performance achievements with PET. Gambro BCT has previously released information on the use of Riboflavin (vitamin B₂) to inactivate viruses and bacteria in platelets and plasma.

Dr. Ray Goodrich and Dr. Mike McAteer, Therapy Scientists for Gambro BCT, will both be presenting information on PET red blood cell performance at the American Association of Blood Banks (AABB) annual meeting in Washington, DC. Dr. Goodrich will present a paper entitled "Inactivation of Pathogens In Blood Products By Riboflavin and Light" and Dr. McAteer will present a poster entitled "Photoinactivation of Virus in Packed Red Blood Cell Units using Riboflavin and Visible Light." These presentations provide an industry update on new capabilities of the Riboflavin-based PET process to inactivate pathogens in red blood cell (RBC) products. PET has now demonstrated the ability to inactivate significant levels of virus including bovine viral diarrhea virus (BVDV), Pseudorabies virus, phi6 and phiX174 in RBC products. With BVDV, a model for the human hepatitis C virus, Pseudorabies virus, a model for CMV and Herpes viruses, and phi6, a model for HIV, Gambro BCT demonstrated inactivation of ≥ 5 logs which represents complete inactivation of these viruses.

Riboflavin used in the PET development program is the first compound that can inactivate pathogens in all three major blood components: red blood cells, platelets and fresh frozen plasma. With more than 48 million red blood cell transfusions annually to patients around the world, the potential market size for RBC pathogen inactivation technology is USD 1.7 billion.

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 18,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com

November 3, 2000

Gambro's PET program continues to make significant advancements in Riboflavin-based pathogen inactivation research toward its goal of a safe and trusted blood supply. Additional information on PET research is available on the Gambro BCT website; gambrobct.com.

For more information on PET technology, call David Perez, President, Gambro BCT, tel # +1-303-232-6800 or visit their Website at www.gambrobct.com.

For more information on Gambro, contact Bengt Modeer, Senior Vice President, Corp. Communications, tel # +46 8 6136500 or +46 70 5136533. www.gambro.com.

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 18,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com